Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 4 (2007), Issue 3 (March)

1. Canine cognitive dysfunction and the cerebellum: acetylcholinesterase reduction, neuronal and glial changes.
   Brain Res, 1139: 85-94. [Abstract] [Full-text]
2. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians.
   Brain Res, 1139: 1-5. [Abstract] [Full-text]
3. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.
   Neurology, 68(10): 757-63. [Abstract] [Full-text]
4. Structure nor stability of the transmembrane spanning 6/7 domain of presenilin I correlates with pathogenicity.
   Biochem Biophys Res Commun, 355(3): 820-4. [Abstract] [Full-text]
5. Sleep disturbances in caregivers of persons with dementia: contributing factors and treatment implications.
   Sleep Med Rev, 11(2): 143-53. [Abstract] [Full-text]
6. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
   Psychopharmacology (Berl), 191(4): 1005-14. [Abstract] [Full-text]
7. Genetic association between polymorphisms of Pen2 gene and late onset Alzheimer's disease in the North Chinese population.
   Brain Res, 1141: 10-4. [Abstract] [Full-text]
8. Cerebrospinal fluid antimicroglial antibodies in Alzheimer disease: a putative marker of an ongoing inflammatory process.
   Exp Gerontol, 42(4): 355-63. [Abstract] [Full-text]
9. Transthyretin and Alzheimer's disease: where in the brain?
   Neurobiol Aging, 28(5): 713-8. [Abstract] [Full-text]
10. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies.
    Neurobiol Aging, 28(5): 639-47. [Abstract] [Full-text]
11. Weak independent association signals between IDE polymorphisms, Alzheimer's disease and cognitive measures.
    Neurobiol Aging, 28(5): 727-34. [Abstract] [Full-text]
12. Oxidative stress: a bridge between Down's syndrome and Alzheimer's disease.
    Neurobiol Aging, 28(5): 648-76. [Abstract] [Full-text]
13. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease.
    Neurology, 68(11): 828-36. [Abstract] [Full-text]
14. Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease.
    Bioorg Med Chem, 15(7): 2601-10. [Abstract] [Full-text]
15. Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice.
    J Neurosci, 27(11): 2969-78. [Abstract] [Full-text]
16. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease.
    J Neurosci, 27(11): 2727-33. [Abstract] [Full-text]
17. Executive dysfunction screening test for neuropsychiatric disorders.
    Int J Neurosci, 117(4): 507-18. [Abstract] [Full-text]
18. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?
    Lancet Neurol, 6(4): 373-8. [Abstract] [Full-text]
19. 14-3-3 protein beta isoform is associated with 3-repeat tau neurofibrillary tangles in Alzheimer's disease.
    Psychiatry Clin Neurosci, 61(2): 159-67. [Abstract] [Full-text]
20. Decision-making with explicit and stable rules in mild Alzheimer's disease.
    Neuropsychologia, 45(8): 1632-41. [Abstract] [Full-text]
21. Visual and visuospatial short-term memory in mild cognitive impairment and Alzheimer disease: role of attention.
    Neuropsychologia, 45(8): 1948-60. [Abstract] [Full-text]
22. Category-specific naming deficit in Alzheimer's disease: the effect of a display by domain interaction.
    Neuropsychologia, 45(8): 1832-9. [Abstract] [Full-text]
23. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease.
    J Neurol Neurosurg Psychiatry, 78(4): 350-5. [Abstract] [Full-text]
24. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography.
    J Neurol Neurosurg Psychiatry, 78(4): 356-62. [Abstract] [Full-text]
25. Decrease of dehydrogenase activity of cerebral glyceraldehyde-3-phosphate dehydrogenase in different animal models of Alzheimer's disease.
    Biochim Biophys Acta, 1770(5): 826-32. [Abstract] [Full-text]
26. Pin1 in Alzheimer's disease: multiple substrates, one regulatory mechanism?
    Biochim Biophys Acta, 1772(4): 422-9. [Abstract] [Full-text]
27. Lymphocyte G-protein-coupled receptor kinase-2 is upregulated in patients with Alzheimer's disease.
    Neurosci Lett, 415(3): 279-82. [Abstract] [Full-text]
28. Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study.
    Neuroimage, 35(2): 488-500. [Abstract] [Full-text]
29. Linking cell-cycle dysfunction in Alzheimer's disease to a failure of synaptic plasticity.
    Biochim Biophys Acta, 1772(4): 413-21. [Abstract] [Full-text]
30. The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development.
    Biochim Biophys Acta, 1772(4): 503-8. [Abstract] [Full-text]
31. Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease.
    Biochim Biophys Acta, 1772(4): 438-45. [Abstract] [Full-text]
32. The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease.
    Biochim Biophys Acta, 1772(4): 402-8. [Abstract] [Full-text]
33. Alzheimer disease, the two-hit hypothesis: an update.
    Biochim Biophys Acta, 1772(4): 494-502. [Abstract] [Full-text]
34. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes.
    Biochim Biophys Acta, 1772(4): 467-72. [Abstract] [Full-text]
35. Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia.
    Neurology, 68(12): 927-31. [Abstract] [Full-text]
36. Testing for linkage and association across the dihydrolipoyl dehydrogenase gene region with Alzheimer's disease in three sample populations.
    Neurochem Res, 32(4): 857-69. [Abstract] [Full-text]
37. Indices of metabolic dysfunction and oxidative stress.
    Neurochem Res, 32(4): 717-22. [Abstract] [Full-text]
38. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?
    Neurochem Res, 32(4): 845-56. [Abstract] [Full-text]
39. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration.
    Neurosci Lett, 416(1): 66-70. [Abstract] [Full-text]
40. Alzheimer's disease and cholesterol: the fat connection.
    Neurochem Res, 32(4): 739-50. [Abstract] [Full-text]
41. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms.
    Neurochem Res, 32(4): 751-6. [Abstract] [Full-text]
42. Alzheimer disease--no target for statin treatment. A mini review.
    Neurochem Res, 32(4): 695-706. [Abstract] [Full-text]
43. Increased expression of p130 in Alzheimer disease.
    Neurochem Res, 32(4): 639-44. [Abstract] [Full-text]
44. The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid.
    Neurochem Res, 32(4): 609-23. [Abstract] [Full-text]
45. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia.
    Neurochem Res, 32(4): 555-67. [Abstract] [Full-text]
46. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients.
    Am J Geriatr Psychiatry, 15(4): 354-6. [Abstract] [Full-text]
47. Prevalence and impact of paratonia in Alzheimer disease in a multiracial sample.
    Am J Geriatr Psychiatry, 15(4): 351-3. [Abstract] [Full-text]
48. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease.
    Am J Geriatr Psychiatry, 15(4): 314-27. [Abstract] [Full-text]
49. Effects of placement and bereavement on psychological well-being and cardiovascular risk in Alzheimer's caregivers: a longitudinal analysis.
    J Psychosom Res, 62(4): 439-45. [Abstract] [Full-text]
50. ABCA1 polymorphisms and Alzheimer's disease.
    Neurosci Lett, 416(2): 180-3. [Abstract] [Full-text]
51. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.
    Neurobiol Dis, 26(1): 273-81. [Abstract] [Full-text]
52. Homocysteine and electroencephalographic rhythms in Alzheimer disease: a multicentric study.
    Neuroscience, 145(3): 942-54. [Abstract] [Full-text]
53. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease.
    Neurobiol Dis, 26(1): 212-20. [Abstract] [Full-text]
54. Differential regulation of inhibitors of apoptosis proteins in Alzheimer's disease brains.
    Neurobiol Dis, 26(1): 165-73. [Abstract] [Full-text]
55. Religious beliefs and practices are associated with better mental health in family caregivers of patients with dementia: findings from the REACH study.
    Am J Geriatr Psychiatry, 15(4): 292-300. [Abstract] [Full-text]
56. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study.
    Neurology, 68(13): 1032-8. [Abstract] [Full-text]
57. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Neurology, 68(13): 1008-12. [Abstract] [Full-text]
58. Insight and danger in Alzheimer's disease.
    Eur J Neurol, 14(4): 455-60. [Abstract] [Full-text]
59. Cognitive and behavioural predictors of progression rates in Alzheimer's disease.
    Eur J Neurol, 14(4): 440-6. [Abstract] [Full-text]
60. Preclinical vascular cognitive impairment and Alzheimer disease: neuropsychological test performance 5 years before diagnosis.
    Stroke, 38(4): 1148-53. [Abstract] [Full-text]
61. Activation of caspase-6 in aging and mild cognitive impairment.
    Am J Pathol, 170(4): 1200-9. [Abstract] [Full-text]
62. Techniques for early detection of Alzheimer's disease using spontaneous EEG recordings.
    Physiol Meas, 28(4): 335-47. [Abstract] [Full-text]
63. Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease.
    Prog Neuropsychopharmacol Biol Psychiatry, 31(3): 746-51. [Abstract] [Full-text]
64. Application and comparison of classification algorithms for recognition of Alzheimer's disease in electrical brain activity (EEG).
    J Neurosci Methods, 161(2): 342-50. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.